Rezolute shares surge 10.55% after-hours after sharing Phase 3 sunRIZE study insights and expanded access program findings.

Rezolute (RZLT) surged 10.55% in after-hours trading, driven by the company’s disclosure of insights from its Phase 3 sunRIZE study in congenital hyperinsulinism and updates on its expanded access program in tumor hyperinsulinism. The announcement, reported by GlobeNewswire, highlighted data from the failed Phase 3 trial while emphasizing ongoing efforts to expand access to its drug candidate, ersodetug. This development, coupled with recent insider buying by Chief Financial Officer Daron Evans, who increased his stake by 21%, provided a near-term catalyst for investor optimism despite prior setbacks from the trial’s failure. The move contrasts with earlier month-to-date declines linked to the Phase 3 results but reflects renewed focus on the drug’s potential in alternative applications.